Related Experiment Video
Updated: Jun 23, 2026
Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021
Clinical Oncologist and NHS Commissioner Perspectives on Reirradiation for Recurrent Cancer
F Slevin1, S Kendal2, A L Appelt1
1Radiotherapy Research Group, Leeds Institute of Medical Research, University of Leeds, Leeds, UK; Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Aims:
There is increasing interest in the potential benefits of reirradiation of recurrent or new primary cancer close to or within a previously irradiated region but there is a need for high-quality studies to evaluate this approach. This study aimed to understand clinician and NHS commissioner perspectives, methods for evidence generation, and the potential role of advanced technologies.
Materials And Methods:
Semi-structured interviews were conducted with UK clinical oncologists and commissioners. Analysis was informed by principles of thematic analysis.
Results:
Interviews were conducted and analysed with 10 clinical oncologists and 2 commissioners. Six themes were developed: 1. Weighing potential benefits against uncertainties; 2. Considering patient preferences in clinical decision-making; 3. A desire for clear guidance on planning and delivering reirradiation; 4. Challenges in the availability of reirradiation; 5. A desire for a stronger evidence-base to guide clinical care; 6. Considerations for clinical trial design. Clinicians and commissioners were supportive of strengthening the evidence base and increasing availability of reirradiation. Some clinicians and both commissioners favoured doing so using clinical trials whereas others considered prospective registries or evaluative commissioning to be more feasible. The potential benefits that could be gained from advanced technologies were highlighted, but also that many patients could benefit from high-quality standard photon reirradiation.
Conclusion:
This study provides important insights into reirradiation practice and how to improve its availability. Perspectives regarding trials and advanced technologies should shape future study design to strengthen the evidence base.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Nursing Ethical Principles II
Consider the following scenario, which illustrates how these principles are applied in the care of Mr. John, a fifty-year-old teacher diagnosed with metastatic liver cancer.
Initially, Mr. John's cancer...
01:27Tumor Immunotherapy